ArticleCancer cell international2026
Low frequency and rare coding variants affect susceptibility and progression of childhood acute lymphoblastic leukemia.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
This study aimed to explore the potential genetic underpinnings of childhood acute lymphoblastic leukemia (ALL). Initially, an exome-wide association analysis of 89 ALL survivors and 356 controls was conducted to identify candidate genes, incorporating single-variant tests and annotation-weighted aggregation tests. Single-cell analyses characterized the candidate genes’ biological context, while aggregate testing linked these genes to clinical traits in survivors, along with bulk tissue transcriptomes profiling their expression patterns in relation to secondary adverse events (e.g., progression, relapse, secondary malignant neoplasms or death). Results from single-variant tests showed that rs57421986 of hematology-related gene SPTB exhibited a suggestive association with ALL [minor allele frequency = 0.029, odds ratio (OR) = 21.7, P = 5.86 × 10− 5]. Aggregation tests of low-frequency and rare variants identified MFAP3L (P = 3.97 × 10− 8), CARD11 (P = 4.18 × 10− 8), NOL8 (P = 2.46 × 10− 10), and OR7G2 (P = 2.20 × 10− 7) as ALL-associated genes. Notably, CARD11 and NOL8 demonstrated differential expression across diverse immune cells between incident cases and controls. Clinical phenome analyses linked CARD11 to mean corpuscular hemoglobin (P = 4.32 × 10− 2), alkaline phosphatase (P = 4.33 × 10− 2), and free triiodothyronine (P = 4.85 × 10− 2), NOL8 to red blood cell count (P = 2.83 × 10− 4) and mean corpuscular volume (P = 2.04 × 10− 3), and OR7G2 to thyroid-stimulating hormone (P = 9.56 × 10− 3) and alkaline phosphatase levels (P = 3.07 × 10− 2). Furthermore, a higher expression of OR7G2 at diagnosis showed a suggestive association with the occurrence of secondary adverse events (P = 0.034). Our findings provide initial clues regarding the shared genetic factors underlying both ALL onset and prognosis. These insights may offer potential guidance for refined risk stratification and personalized survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.